AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
暂无分享,去创建一个
M. Salto‐Tellez | P. Johnston | D. Longley | D. McArt | P. Dunne | M. Kalimutho | J. Blayney | S. Van Schaeybroeck | S. Srivastava | C. Ong | M. Loughrey | Tingting Wang | K. Redmond | K. Arthur | Samanda Greer
[1] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[2] D. Sargent,et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.
[3] M. Salto‐Tellez,et al. Lgr5 expression is absent in human premalignant lesions of the stomach , 2012, Gut.
[4] Hui Gao,et al. Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy , 2011, International journal of cancer.
[5] Chien-Hsing Lee,et al. Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma , 2012, Annals of Surgical Oncology.
[6] Sridhar Ramaswamy,et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Salto‐Tellez,et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.
[8] Li Lin,et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.
[9] Chih-Yang Huang,et al. CD133/Src Axis Mediates Tumor Initiating Property and Epithelial-Mesenchymal Transition of Head and Neck Cancer , 2011, PloS one.
[10] S. Liyanarachchi,et al. Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. , 2011, Neoplasia.
[11] Sharmila Shankar,et al. Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells , 2011, PloS one.
[12] M. Salto‐Tellez,et al. Sequential expression of putative stem cell markers in gastric carcinogenesis , 2011, British Journal of Cancer.
[13] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[14] Shuji Ogino,et al. STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers , 2011, Clinical Cancer Research.
[15] P. Johnston,et al. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. , 2011, Cancer research.
[16] Dennis B. Troup,et al. NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..
[17] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. V. van't Veer,et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Stuart Thomson,et al. A systems view of epithelial–mesenchymal transition signaling states , 2010, Clinical & Experimental Metastasis.
[20] E. Montgomery,et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma , 2010, Cancer biology & therapy.
[21] H. Earp,et al. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors , 2010, Expert opinion on therapeutic targets.
[22] P. Johnston,et al. Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer , 2010, Clinical Cancer Research.
[23] M. Todaro,et al. Colon cancer stem cells: promise of targeted therapy. , 2010, Gastroenterology.
[24] T. Yeatman,et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.
[25] Y. Hitoshi,et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.
[26] M. Salto‐Tellez,et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer , 2010, Modern Pathology.
[27] Bjørn Tore Gjertsen,et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.
[28] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[29] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[30] P. Johnston,et al. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. , 2008, Cancer research.
[31] Ming-Tseh Lin,et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.
[32] Stuart Thomson,et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.
[33] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[34] N. Petrelli,et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] David M. Thomas,et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer , 2006, BMC Cancer.
[36] B. Dahlbäck,et al. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. , 2006, Cytokine & growth factor reviews.
[37] M. Essig,et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[38] Y. Chu,et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. , 2005, Neoplasia.
[39] T. Wilson,et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP , 2005, Molecular Cancer Therapeutics.
[40] P. Johnston. Stage II colorectal cancer: to treat or not to treat. , 2005, The oncologist.
[41] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[42] M. Meyers,et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.
[43] M. Salgaller. American Association for Cancer Research , 2000, Expert opinion on investigational drugs.
[44] E. Ruaro,et al. Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras , 1999, Oncogene.
[45] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[46] C. Basilico,et al. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding , 1995, Molecular and cellular biology.
[47] J. Izbicki,et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.
[48] S. Shirasawa,et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.
[49] A. Schulz,et al. A novel putative tyrosine kinase receptor with oncogenic potential. , 1991, Oncogene.
[50] R. Espinosa,et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase , 1991, Molecular and cellular biology.